Abstract

During intracellular infection, T follicular helper (TFH) and T helper 1 (TH1) cells promote humoral and cell-mediated responses, respectively. Another subset, CD4-cytotoxic T lymphocytes (CD4-CTLs), eliminate infected cells via functions typically associated with CD8+ T cells. The mechanisms underlying differentiation of these populations are incompletely understood. Here, we identify the transcription factor Aiolos as a reciprocal regulator of TFH and CD4-CTL programming. We find that Aiolos deficiency results in downregulation of key TFH transcription factors, and consequently reduced TFH differentiation and antibody production, during influenza virus infection. Conversely, CD4-CTL programming is elevated, including enhanced Eomes and cytolytic molecule expression. We further demonstrate that Aiolos deficiency allows for enhanced IL-2 sensitivity and increased STAT5 association with CD4-CTL gene targets, including Eomes, effector molecules, and IL2Ra. Thus, our collective findings identify Aiolos as a pivotal regulator of CD4-CTL and TFH programming and highlight its potential as a target for manipulating CD4+ T cell responses.

The regulation and direction of CD4+ T cells into phenotypic and functional lineages is coordinated by a complex set of mechanisms. Here the authors show a role for Aiolos as a regulator of the CD4+ cytotoxic and T follicular helper lineages.

Details

Title
Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity
Author
Read, Kaitlin A. 1 ; Jones, Devin M. 1 ; Pokhrel, Srijana 2 ; Hales, Emily D. S. 2 ; Varkey, Aditi 2 ; Tuazon, Jasmine A. 3 ; Eisele, Caprice D. 4 ; Abdouni, Omar 2 ; Saadey, Abbey 1 ; Leonard, Melissa R. 5   VIAFID ORCID Logo  ; Warren, Robert T. 2 ; Powell, Michael D. 6 ; Boss, Jeremy M. 6 ; Hemann, Emily A. 7 ; Yount, Jacob S. 7 ; Xin, Gang 8 ; Ghoneim, Hazem E. 8   VIAFID ORCID Logo  ; Lio, Chan-Wang J. 8 ; Freud, Aharon G. 9   VIAFID ORCID Logo  ; Collins, Patrick L. 8   VIAFID ORCID Logo  ; Oestreich, Kenneth J. 10   VIAFID ORCID Logo 

 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4); Medical Scientist Training Program, Columbus, USA (GRID:grid.261331.4) 
 Biomedical Sciences Graduate Program, Columbus, USA (GRID:grid.261331.4); The Ohio State University College of Medicine and Wexner Medical Center, Department of Pathology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Veterinary Medicine, Combined Anatomic Pathology Residency/PhD Program, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943) 
 Emory University School of Medicine, Department of Microbiology and Immunology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Medicine and Wexner Medical Center, Infectious Diseases Institute, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797) 
 The Ohio State University College of Medicine and Wexner Medical Center, Department of Pathology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797) 
10  The Ohio State University College of Medicine and Wexner Medical Center, Department of Microbial Infection and Immunity, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University College of Medicine and Wexner Medical Center, Infectious Diseases Institute, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, USA (GRID:grid.413944.f) (ISNI:0000 0001 0447 4797) 
Pages
1652
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2790208907
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.